GlycoSeLect Announces Investment & Development Partnership with KBI Biopharma

15th August, 2016. Equity investment in initial funding round, license agreement and development project. Dublin, Ireland & Durham, North Carolina, USA

GlycoSeLect Ltd, specialists in the development and production of glycoprotein separation technology, and KBI Biopharma, Inc., (KBI), a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally, have agreed to an equity investment by KBI in GlycoSeLect as well as a license to GlycoSeLect’s recombinant prokaryotic lectin (RPL) technology.

GlycoSeLect has developed a series of glycan selective RPLs and demonstrated their applicability for the purification and manufacturing of biotherapeutics.

“GlycoSeLect is delighted to announce this investment and development project with an excellent strategic partner,” said Robert Dunne, CEO of GlycoSeLect. “This partnership will further validate our RPL technology for the characterisation and purification of biotherapeutics and will help to demonstrate that our RPLs offer an innovative approach to drug product analysis and separation. We look forward to working with the KBI team on this exciting project”

”We recognize the great potential of the GlycoSeLect RPL technology,” said Dr. Prathima Acharya, Chief Business Development Officer of KBI. “We also see unique opportunities to apply the GlycoSeLect technology for innovative process solutions in several disease areas with unmet patient need.”

GlycoSeLect Ltd is an early-stage biotechnology company developing proprietary next-generation, highly specific and cost-efficient tools for the analysis, characterization and purification of biotherapeutics.Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of RPLs; enhanced glycoselective bioaffinity proteins that enable efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect’s current family of RPLs target a range of galactose and mannose glycoprofiles and are associated with market leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness. GlycoSeLect UK Ltd was established in 2015 to support further development, provide wider geographic reach and drive commercialization.

KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. To date, KBI has helped to advance drug development programs for over 250 clients around the world. KBI offers an extensive suite of expert development and manufacturing services through an agile, science-based and customer-focused approach.